肝动脉灌注化疗联合阿替利珠单克隆抗体与贝伐珠单克隆抗体一线治疗晚期肝细胞癌的临床疗效  

Clinical efficacy of hepatic arterial infusion chemotherapy combined with atelizumab plus bevacizumab on first line treatment of advanced hepatocellular carcinoma

作　　者：叶林森[1] 俞浩远 李思琪 余振宇 汪根树[1] 李洋[1] Ye Linsen;Yu Haoyuan;Li Siqi;Yu Zhenyu;Wang Genshu;Li Yang(Department of Hepatic Surgery&Liver Transplantation,Organ Transplantation Research Institute,Organ Transplantation Research Center of Guangdong Province,Transplantation Medical Engineering Laboratory of Guangdong Province,the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510515,China)

机构地区：[1]中山大学附属第三医院肝脏外科暨肝移植中心、中山大学器官移植研究所、广东省器官移植研究中心、广东省移植医学工程实验室,广州510515

出　　处：《中华消化外科杂志》2022年第S01期5-9,共5页Chinese Journal of Digestive Surgery

摘　　要：晚期肝癌治疗手段有限,预后不佳,严重危害人民健康。局部联合系统性治疗模式在晚期肝细胞癌患者治疗中愈发重要。临床研究证实:阿替利珠单克隆抗体联合贝伐珠单克隆抗体可以为晚期肝细胞癌患者带来更好的生存获益。笔者报道1例中国肝癌分期Ⅲa期肝癌患者行肝动脉灌注化疗局部治疗联合阿替利珠单克隆抗体+贝伐珠单克隆抗体转化治疗的临床经验。其研究结果显示:患者成功转化后行手术切除,取得良好效果。The treatment of advanced hepatocellular carcinoma(HCC)is limited and the prognosis is poor,which seriously endangers the public health.Results of clinical trials have confirmed the validity of atelizumab plus bevacizumab in patients with advanced HCC.The authors introduce the clinical experience of a patient with stageⅢa HCC undergoing local therapy of hepatic artery chemoembolization,and combined with atelizumab plus bevacizumab.The results show that patient with successfully transformational therapy,and receiving surgical resection with a good clinical effect.

关 键 词：肝肿瘤 免疫治疗 靶向治疗 联合治疗 转化治疗 

分 类 号：R735.7[医药卫生—肿瘤]